Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients.

J. Małyszko,J. Małyszko,H. Bachórzewska-Gajewska,B. Poniatowski,S. Dobrzycki,M. Myśliwiec

DOI: https://doi.org/10.1016/j.transproceed.2008.10.088

IF: 1.014

Transplantation Proceedings

Abstract:

What problem does this paper attempt to address?

Molecular Mechanism of Anti-Cancer Activity of the Nano-Drug C-PC/CMC-CD59sp NPs in Cervical Cancer

Liangqian Jiang,Yujuan Wang,Feng Zhu,Guoxiang Liu,Huihui Liu,Huanhuan Ji,Shuhua Zheng,Bing Li

DOI: https://doi.org/10.7150/jca.27462

IF: 3.9

2019-01-01

Journal of Cancer

Abstract:The novel tumor targeted nano-drug C-PC/CMC-CD59sp nanoparticles were constructed with carbocymethyl chitosan (CMC), C-phycocyanin (C-PC) and CD59 specific ligand peptide (CD59sp). The anti-tumor drug mechanism of the C-PC/CMC-CD59sp NPs was further explored in cervical cancer cells (HeLa and SiHa) in vitro and in vivo. We found that the C-PC/CMC-CD59sp NPs could inhibit the proliferation and induce G0/G1 cell cycle arrest in cervical cancer HeLa and SiHa cells, and the cell proliferation was reduced in a dose-dependent manner. We further found that the C-PC/CMC-CD59sp NPs regulated the cell cycle via up-regulating the expression of p21, and then down-regulating the expressions of Cyclin D1 and CDK4 in vivo. Compared with C-PC and C-PC/CMC NPs, the pro-apoptosis effects of the C-PC/CMC-CD59sp NPs were more significant for HeLa and SiHa cells in vitro. Moreover, the C-PC/CMC-CD59sp NPs up-regulated the expression of cleaved caspase-3 and down-regulated the expression of bcl-2. In addition, compared with C-PC and C-PC/CMC, the C-PC/CMC-CD59sp NPs significantly inhibited MMP-2 protein expression in vivo. Our data suggested that the anti-tumor effects of C-PC/CMC-CD59sp NPs were better than C-PC and C-PC/CMC NPs. Our laboratory constructed a new drug delivery system and proved the effective antitumor effects of C-PC/CMC-CD59sp, which would widen the application of C-PC as a potential anti cervical cancer drug.

oncology
A novel navigated doxorubicin delivery formulation to breast cancer therapy

Sinan Cheng,Zheng Lu,Yang Feng,Xuewei Zhao,Ruixia Zhao,Zuchun Qiu,Chenshuang Jia,Lirong Chen,Yue Yuan,Xinyao Li,Qian Gao,Jie Xu,Zhan Shu,Wei Duan,Yingchun Hou,Guochao Nie,Li Xiao

DOI: https://doi.org/10.1016/j.mtadv.2022.100235

IF: 9.918

2022-06-01

Materials Today Advances

Abstract:Breast cancer (BC) is the most frequently diagnosed cancer and leading cause of the death in women. Current chemotherapy usually results in poor prognosis with low treatment efficacy and high side effects because of weak targeting specificity and fast elicitation of multidrug resistance (MDR). It is emergently needed to develop a novel BC targeting drug delivery formulation for the chemotherapy of BC and drug resistant BC. In our study, we screened out BC targeting 12-mer peptide (BSP1) from a phage-displayed peptide library, then a novel doxorubicin (DOX) delivery formulation (BSP1-Lipo-DOX-miR101) targeting BC automatically was synthesized and used in a series of experiments to test its efficacy of chemotherapy of BC and DOX resistant BC in vitro. The consequently results indicated that BSP1 bound to MCF-7 cells and BC tissues specifically and sensitively with high affinity, the BC automatically targeted drug vehicles exhibited its high specificity for BC targeting, marked suppression for the development of cell motility relevant microstructures, such as the polymerization of the pseudopodia and filopodia in MCF-7 and MCF-7/ADR cells. The novel drug formulation presented the satisfied therapeutic efficacy for BC therapy, particularly for DOX resistant BC in vitro. The results of western blot explored the potential mechanism by that BSP1-Lipo-DOX-miR101 inhibits the expression of EMT (epithelial/endothelial mesenchymal transition) and MDR relevant genes. Our current results provide a novel chemotherapeutic formulation with precise, satisfying therapeutic efficacy to improve the current poor BC clinical prognosis including drug resistant BC.

materials science, multidisciplinary
The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with High-Affinity Peptides Discovered by Phage Display.

Haoran Zhang,Zhaoming Guo,Bing He,Wenbing Dai,Hua Zhang,Xueqing Wang,Qiang Zhang

DOI: https://doi.org/10.1002/adhm.201800269

IF: 10

2018-01-01

Advanced Healthcare Materials

Abstract:Ligand-targeted nanosystems have the potential to realize site-specific tumor therapy and alleviate unwanted side effects of many chemotherapeutic agents, and one of the most key issues seems to be the construction of an effective nanocarrier. Based on different processes of phage display techniques, 38 cell-binding peptides and 32 cell-internalizing peptides are discovered. Four of these ligand peptides [FIPFDPMSMRWE (FIP), NASSFPTNSRWA (NAS), GLHTSATNLYLH (GLH), and ALAVAPSRWWNE (ALA), respectively] exhibit high affinity to MCF7 human breast cancer cells. Among them, NAS and ALA are reported for the first time, whose affinities are 20.6 and 76.3 times that of the random peptide control, respectively. Both NAS and ALA modifications to doxorubicin-loaded lipid nanosytems [LP(DOX)] show stronger tumor inhibition, longer animal survival time, and less body weight loss, compared to unmodified or control peptide modified nanosystems, on an MCF7 tumor-bearing mouse model. In conclusion, the cell-binding peptide NAS and cell-internalizing peptide ALA can be used for ligand-targeted delivery of antitumor drugs. It seems that the in vivo antitumor effect of these ligand-targeted nanosystems is closely related to their ligand-cell affinity, but fairly tolerant of the ligand types.
Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging.

Ruei-Min Lu,Min-Shan Chen,De-Kuan Chang,Chien-Yu Chiu,Wei-Chuan Lin,Shin-Long Yan,Yi-Ping Wang,Yuan-Sung Kuo,Chen-Yun Yeh,Albert Lo,Han-Chung Wu

DOI: https://doi.org/10.1371/journal.pone.0066128

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Targeted delivery of drugs to tumors represents a significant advance in cancer diagnosis and therapy. Therefore, development of novel tumor-specific ligands or pharmaceutical nanocarriers is highly desirable. In this study, we utilized phage display to identify a new targeting peptide, SP90, which specifically binds to breast cancer cells, and recognizes tumor tissues from breast cancer patients. We used confocal and electron microscopy to reveal that conjugation of SP90 with liposomes enables efficient delivery of drugs into cancer cells through endocytosis. Furthermore, in vivo fluorescent imaging demonstrated that SP90-conjugated quantum dots possess tumor-targeting properties. In tumor xenograft and orthotopic models, SP90-conjugated liposomal doxorubicin was found to improve the therapeutic index of the chemotherapeutic drug by selectively increasing its accumulation in tumors. We conclude that the targeting peptide SP90 has significant potential in improving the clinical benefits of chemotherapy in the treatment and the diagnosis of breast cancer.
A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

Hui Ye,Xiaoying Chu,Zhensheng Cao,Xuanxuan Hu,Zihan Wang,Meiqi Li,Leyu Wan,Yongping Li,Yongge Cao,Zhanqiu Diao,Fengting Peng,Jinsong Liu,Lihua Xu

DOI: https://doi.org/10.2147/IJN.S258316

IF: 7.033

2021-02-12

International Journal of Nanomedicine

Abstract:Hui Ye, 1, * Xiaoying Chu, 1, * Zhensheng Cao, 2, * Xuanxuan Hu, 1, * Zihan Wang, 2 Meiqi Li, 1 Leyu Wan, 2 Yongping Li, 3 Yongge Cao, 4 Zhanqiu Diao, 2 Fengting Peng, 2 Jinsong Liu, 2 Lihua Xu 5 1 School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China; 2 School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China; 3 Department of Surgery, Chengdu Shuangliu District Maternal and Child Health Hospital, ChengDu, Sichuan, 610200, People's Republic of China; 4 Department of Stomatology, Haiyuan College, Kunming, Yunnan, 650106, People's Republic of China; 5 Department of General Medicine, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, People's Republic of China *These authors contributed equally to this work Correspondence: Hui Ye School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China Email wmcyh@wmu.edu.cn Lihua Xu Department of General Medicine, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China Email lihuaxu@wmu.edu.cn Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer. Methods: Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined. Results: The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery. Conclusion: The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer. Keywords: magnetic thermosensitive cationic liposome, oxaliplatin, antisense lncRNA of MDC1, targeted therapy, cervical cancer

pharmacology & pharmacy,nanoscience & nanotechnology
Ca2+ signaling modulation using cancer cell membrane coated chitosan nanoparticles to combat multidrug resistance of cancer

Zhao Zhao,Mei Ji,Qianqing Wang,Nannan He,Yue Li

DOI: https://doi.org/10.1016/j.carbpol.2020.116073

2020-06-15

Abstract:Off-target drug delivery, together with multidrug resistance (MDR), are two keys obstacles that account for the disappointing outcome in clinical chemotherapy of cancer. To solve these dilemmas, Herein, we constructed cancer cell membrane (CCM) modified silica (CS) nanoparticles (CCM/CS) to co-deliver Ca2+ channel siRNA with doxorubicin (DOX) to construct a platform (CCM/CS/R-D) for the efficient therapy of cervical cancer. It was demonstrated that the optimal CCM/CS/R-D was spherical nanoparticles with size at 122.39 ± 4.69 nm and the surface charge of -27.76 ± 3.12 mV. In addition, the CCM/CS/R-D showed acid responsive drug release while high stability under physiological conditions with negligible hemolysis. The CCM/CS/R-D showed CCM mediated cellular uptake and efficient endosomal escape as well as siRNA transfection potential (comparable to that of PEI 25 K) on MDR cervical cancer cells (HeLa/DOX). Most importantly, the MDR of cancer cells was conquered through modulation of T-type Ca2+ (Cav) channels. It was observed that the Cav channel siRNA could negatively regulate the level of cytosolic Ca2+ concentration which triggered G0/G1 phase cell cycle arrest and elevated intracellular drug retention in HeLa/DOX cells without significantly affect the expression of P-glycolprotein (P-gp). The in vitro and in vivo experiments revealed that CCM/CS/R-D exerted greatly enhanced tumor targetability and therapeutic effect on HeLa/DOX, which was superior than CS/R-D or mono delivery system (CCM/CS/R or CCM/CS/D).
Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Bao Li,Haoran Niu,Xiaoyun Zhao,Xiaoyu Huang,Yu Ding,Ke Dang,Tianzhi Yang,Yongfeng Chen,Jizhuang Ma,Xiaohong Liu,Keda Zhang,Huichao Xie,Pingtian Ding

DOI: https://doi.org/10.1016/j.ajps.2024.100891

IF: 9.273

2024-02-01

Asian Journal of Pharmaceutical Sciences

Abstract:Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.

pharmacology & pharmacy
Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell

Zixuan Xiao,Keying Chen,Tong Lin,Pengkai Zhao,Haixia Wang,Zhiqiang Su

DOI: https://doi.org/10.1016/j.mtcomm.2024.110404

IF: 3.8

2024-09-23

Materials Today Communications

Abstract:Breast cancer become the most prevalent malignancy and is rising up to the first leading cause of cancer-related mortality among the female people globally. Approaches for safe, specific targeting and efficient inhibition of breast cancer cells, are urgently demanded for lifting the survival rate of breast tumor-bearing patients. Herein, a versatile hydrogel drug carrier consisting of doxorubicin (DOX)-loaded hydrogel microsphere and carbon dots (CDs)-loaded peptide nanowires (DOX@PEG/PNFs-CDs) was constructed, presenting specific targeting and synergistic anti-cancer cell potencies. The hydrogel PEG microspheres with a rich porous structure benefited the drug loading efficiency, demonstrating good biodegradability and higher drug release efficiency at acidic environment. Benefiting from the RGD group of the peptide nanowires, the drug-loaded system specific targeted onto the MDA-MB-231 cells, subsequently promoting the synergistic inhibition of the cancer cell growth by DOX and metformin derived CDs. This all-in-one smart drug carrier post a promising strategy for breast cancer treatment.

materials science, multidisciplinary
A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Dandan Zhu,Huanle Zhang,Yuanzheng Huang,Baoping Lian,Chi Ma,Lili Han,Yu Chen,Shengmei Wu,Ning Li,Wenjie Zhang,Xiaoxuan Liu

DOI: https://doi.org/10.3390/pharmaceutics13071092

IF: 6.525

2021-07-17

Pharmaceutics

Abstract:Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK2 and AmPD KK2K4). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK2 bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK2K4 bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK2 maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.

pharmacology & pharmacy
Core-shell Tecto Dendrimers Co-Deliver Drug/gene for Immunomodulation of Macrophages and Dendritic Cells and Checkpoint Blockade-Promoted Breast Cancer Chemoimmunotherapy

Cong Song,Zhijun Ouyang,Junjie Liu,Mengsi Zhan,Zinuo Zhang,Mingwu Shen,Shuanglian Wang,Xiangyang Shi,Shaojun Peng

DOI: https://doi.org/10.1016/j.nantod.2024.102437

IF: 17.4

2024-01-01

Nano Today

Abstract:Development of an advanced drug formulation to cancer cells that can result in immunomodulation of multiple immune cells for enhanced cancer immunotherapy remains to be challenging. Herein, we developed a co-delivery strategy based on pH-sensitive core-shell tecto dendrimers (CSTDs) to simultaneously deliver CD47 siRNA and anticancer drug doxorubicin (DOX) to cancer cells to lead to downregulation of “don't eat me” signals through silencing the CD47 genes for enhanced macrophage recognition, and upregulation of “eat me” signals through chemotherapy-mediated calreticulin exposure for promoted dendritic cell (DC) maturation and subsequent cytotoxic T cell activation, respectively. We show that the developed pH-responsive CSTDs are a robust vector that can compress siRNA and physically load DOX simultaneously with a high loading efficiency and a loading content, and can fast release the drug in an acidic tumor microenvironment. Importantly, with the combined anti-cytotoxic T-lymphocyte-associated protein 4 antibody-mediated immune checkpoint blockade, the CSTDs-mediated drug/gene delivery enables synergistically promoted M1 polarization of macrophages and T cell-mediated immune responses to effectively inhibit both primary and distal murine breast tumors. Such a development of CSTD-based drug/gene co-delivery to cancer cells that can simultaneously modulate multiple immune cells provides new insights for enhanced immunotherapy of different types of cancer.
The association of placental abnormalities with maternal and neonatal clinical findings: a retrospective cohort study.

S. Rhone,F. Magee,V. Remple,D. Money

DOI: https://doi.org/10.1016/S1701-2163(16)30208-0

2003-02-01

Journal of Obstetrics and Gynaecology Canada

Abstract:
Peptide-conjugated Nanoparticles for Targeted Imaging and Therapy of Prostate Cancer

Chen-Yun Yeh,Jong-Kai Hsiao,Yi-Ping Wang,Chun-Hsin Lan,Han-Chung Wu

DOI: https://doi.org/10.1016/j.biomaterials.2016.05.015

IF: 14

2016-01-01

Biomaterials

Abstract:While there has been extensive development of anti-cancer drugs for treatment of prostate cancer, the therapeutic efficacy of such drugs remains inadequate in many cases. Here, we performed in vitro biopanning of the PC3 human prostate carcinoma cell line to select prostate cancer-specific peptides by phage display. We successfully identified specific peptides targeting prostate cancer cells, and their specificity was confirmed by cellular ELISA and flow cytometry. Moreover, we found that the phage clones also recognize other prostate cancer cell lines and surgical specimens from prostate cancer patients. The tumor targeting ability of these phages was validated in a xenograft model, in which high accumulation of targeting phage was observed. To investigate whether selected peptides are able to target tumors and enhance drug delivery into cancer cells, we synthesized peptide-PEGylated lipids and post-inserted them into preformed liposomal doxorubicin and vinorelbine. The results of our cellular uptake and MTT assays indicate that peptide-conjugated liposomes exhibit enhanced drug intracellular delivery and cytotoxicity. The conjugation of targeting peptide to imaging agents, such as quantum dots (QDs) and superparamagnetic iron oxide nanoparticles (SPIONs), results in more precise delivery of these agents to tumor sites. Furthermore, administration of liposomal doxorubicin and vinorelbine conjugated with targeting peptides was found to markedly increase the inhibition of human prostate tumor growth in mouse xenograft and orthotopic models. These results indicate that targeting peptide, SP204, has significant potential for targeted therapy and molecular imaging in prostate cancer.
Construction of a Targeting Nanoparticle of 3′,3″-Bis-peptide-sirna Conjugate/Mixed Lipid with Postinserted DSPE-PEG2000-cRGD

Yanfen Zhang,Sixiu Li,Xinyang Zhou,Jing Sun,Xinmeng Fan,Zhu Guan,Lihe Zhang,Zhenjun Yang

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00800

2019-01-01

Molecular Pharmaceutics

Abstract:The cyclic Arg-Gly-Asp (cRGD) peptides are widely used as tumor-targeting ligands due to their specific binding ability to integrin αvβ3, which is overexpressed on the surface of various cancer cells and the endothelial cells of new blood vessels within tumor tissues. In this paper, the postinsertion strategy of DSPE-PEG2000-cRGD has been applied to the nanoparticles of 3',3″-bis-peptide-siRNA (pp-siRNA) encapsulated by gemini-like cationic lipid (CLD) and neutral cytosin-1-yl lipid (DNCA) from our lab. It was confirmed that the nanoparticles of pp-siRNA/CLD/DNCA/DSPE-PEG2000-cRGD (PCNR) were able to specifically target tumor cells with highly expressed integrin αvβ3; moreover, it efficiently downregulated the levels of BRAF mRNA and the BRAF protein and inhibited cell proliferation in A375 cells, in comparison with the nontargeted nanocomplex of pp-siRNA/CLD/DNCA/cRAD (PCNA). The uptake pathways of PCNR are mostly dependent on CvME-mediated endocytosis and macropinocytosis in A375 cells, which could bypass lysosome or quickly lead to the lysosomal escape to reduce siRNA degradation. Finally, the biodistribution study showed that PCNR exhibited a high ability to accumulate in tumor tissues. These results suggest that the nanocomplex of PCNR is promising to be highly effective in the treatment of melanomas including their mutation.
Dual-blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.

Guorui Li,Yuan Gao,Chunai Gong,Zhimin Han,Lei Qang,Zongguang Tai,Jing Tian,Shen Gao

DOI: https://doi.org/10.1021/acsami.9b13354

IF: 9.5

2019-01-01

ACS Applied Materials & Interfaces

Abstract:Cancer immunotherapy can enhance the antitumor effect of drugs through a combinatorial approach in a synergistic manner. However, the effective targeted delivery of various drugs remains a challenge. We generated a peptide assembling tumor-targeted nanodelivery system based on a breast cancer homing and penetrating peptide for the codelivery of a programmed cell death ligand 1 (PD-L1) small interfering RNA (siRNA) (siPD-L1) and an indoleamine 2,3-dioxygenase inhibitor as a dual blockade of an immune checkpoint. The vector is capable of specifically accumulating in the breast cancer tumor site in a way that allows the siRNA to escape from endosomal vesicles after being endocytosed by tumor cells. The drug within these cells then acts to block tryptophan metabolism. The results showed that locally released siPD-L1 and 1-methyl-dl-tryptophan favor the survival and activation of cytotoxic T lymphocytes, resulting in apoptosis of breast cancer cells. Therefore, this study provides a potential approach for treating breast cancer by blocking immunological checkpoints through the assembly of micelles with functional peptides.
Cascade-Targeting of Charge-Reversal and Disulfide Bonds Shielding for Efficient DOX Delivery of Multistage Sensitive MSNs-COS-SS-CMC

Lan Cui,Wentao Liu,Hao Liu,Qian Qin,Shuangxia Wu,Suqin He,Zhenya Zhang,Xinchang Pang,Chengshen Zhu

DOI: https://doi.org/10.2147/ijn.s252769

IF: 7.033

2020-08-01

International Journal of Nanomedicine

Abstract:BACKGROUND: Although pH and redox sensitiveness have been extensively investigated to improve therapeutic efficiency, the effect of disulfide bonds location and pH-triggered charge-reversal on cascade-targeting still need to be further evaluated in cancer treatment with multi-responsive nanoparticles.PURPOSE: The aim of this study was to design multi-responsive DOX@MSNs-COS-NN-CMC, DOX@MSNs-COS-SS-CMC and DOX@MSNs-COS-CMC-SS and systematically investigate the effects of disulfide bonds location and charge-reversal on the cancer cell specificity, endocytosis mechanisms and antitumor efficiency.RESULTS: In vitro drug release rate of DOX@MSNs-COS-SS-CMC in tumor environments was 7-fold higher than that under normal physiological conditions after 200 h. Furthermore, the fluorescence intensity of DOX@MSNs-COS-SS-CMC and DOX@MSNs-COS-CMC-SS was 1.9-fold and 1.3-fold higher than free DOX at pH 6.5 and 10 mM GSH. In addition, vesicular transport might be a factor that affects the uptake efficiency of DOX@MSNs-COS-SS-CMC and DOX@MSNs-COS-CMC-SS. The clathrin-mediated endocytosis and endosomal escape of DOX@MSNs-COS-SS-CMC enhanced cellular internalization and preserved highly controllable drug release into the perinuclear of HeLa cells. DOX@MSNs-COS-SS-CMC exhibited a synergistic chemotherapy in preeminent tumor inhibition and less side effects of cardiotoxicity.CONCLUSION: The cascade-targeting of charge-reversal and disulfide bonds shielding would be a highly personalized strategy for cervical cancer treatment.

pharmacology & pharmacy,nanoscience & nanotechnology
Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

Jie Ding,Tingxizi Liang,Ying Zhou,Zhiwei He,Qianhao Min,Liping Jiang,Junjie Zhu

DOI: https://doi.org/10.1007/s12274-016-1328-y

IF: 9.9

2016-01-01

Nano Research

Abstract:Drug resistance renders standard chemotherapy ineffective in the treatment of connective tissue growth factor (CTGF)-overexpressing breast cancer. By co-embedding the breast tumor cell-penetrating peptide (PEGA-pVEC) and hyaluronic acid (HA) as a targeting media, novel cascaded targeting nanoparticles (HACT NPs) were created on a rattle mesoporous silica (rmSiO(2)) scaffold for the pinpoint delivery of siRNAs along with an anticancer drug, aiming at overcoming the drug resistance of CTGF-overexpressing breast cancer in vivo. The targeting nanoparticles selectively accumulated in the vasculature under the guidance of the PEGA-pVEC peptide, cascaded by receptor-mediated endocytosis with the aid of another targeting agent, HA, presenting a greater in vivo tumor targeting ability than single targeting ligand vectors. In addition, an HA shell prevented the leakage of therapeutic drugs during the cargo transport process, until the hyaluronidase (HAase)-triggered degradation upon lysosomes entering, guaranteeing a controllable drug release inside the target cells. When the protective shell disintegrates, the released siRNA took charge to silence the gene associated with drug resistance, CTGF, thus facilitating doxorubicin-induced apoptosis. The cascaded targeting media (PEGA-pVEC and HA) advances precision-guided therapy in vivo, while the encapsulation of siRNAs into a chemotherapy drug delivery system provides an efficient strategy for the treatment of drug resistance cancers.
Sonication can reduce beta-lactamase activity.

W. Nichols,R. Hewinson

Journal of Antimicrobial Chemotherapy

Abstract:
Research priorities on safety of complementary feeding.

Y. Motarjemi

DOI: https://doi.org/10.1542/peds.106.s4.1304

2000-11-01

PEDIATRICS

Abstract:With the introduction of complementary foods, infants are at risk of exposure to foodborne pathogens. Contamination of food (including drinking water) with microbial agents has been recognized as one the leading causes of diarrhea diseases and ill health in infants. It is estimated that annually, some 1.8 million children die from the direct effect of diarrheal diseases. However, many more are affected by the effects associated with diarrheal diseases and malnutrition. It is estimated that annually some 13 million children under 5 years old die in developing countries, mostly from the associated effects of malnutrition and infections. In 1995, out of 11.6 million deaths among children <5, 19% were estimated to have resulted from diarrhea and 54% were associated with malnutrition. Foodborne diseases manifest themselves through a wide a range of symptoms, eg, diarrhea, vomiting, abdominal pain, fever, and jaundice with potentially severe and long-lasting damage to health. Foodborne infections can cause anorexia. A poor food intake, aggravated by the loss of nutrients from vomiting, diarrhea, malabsorption, and fever over an extended period of time, will lead to nutritional deficiencies with serious consequences for the growth and immune system of infants and children. Numerous studies …
Enhancing Sirna-Based Cancer Therapy Using a New Ph-Responsive Activatable Cell-Penetrating Peptide-Modified Liposomal System

Bai Xiang,Xue-Li Jia,Jin-Long Qi,Li-Ping Yang,Wei-Hong Sun,Xiao Yan,Shao-Kun Yang,De-Ying Cao,Qing Du,Xian-Rong Qi

DOI: https://doi.org/10.2147/ijn.s129574

IF: 7.033

2017-01-01

International Journal of Nanomedicine

Abstract:As a potent therapeutic agent, small interfering RNA (siRNA) has been exploited to silence critical genes involved in tumor initiation and progression. However, development of a desirable delivery system is required to overcome the unfavorable properties of siRNA such as its high degradability, molecular size, and negative charge to help increase its accumulation in tumor tissues and promote efficient cellular uptake and endosomal/lysosomal escape of the nucleic acids. In this study, we developed a new activatable cell-penetrating peptide (ACPP) that is responsive to an acidic tumor microenvironment, which was then used to modify the surfaces of siRNA-loaded liposomes. The ACPP is composed of a cell-penetrating peptide (CPP), an acid-labile linker (hydrazone), and a polyanionic domain, including glutamic acid and histidine. In the systemic circulation (pH 7.4), the surface polycationic moieties of the CPP (polyarginine) are “shielded” by the intramolecular electrostatic interaction of the inhibitory domain. When exposed to a lower pH, a common property of solid tumors, the ACPP undergoes acid-catalyzed breakage at the hydrazone site, and the consequent protonation of histidine residues promotes detachment of the inhibitory peptide. Subsequently, the unshielded CPP would facilitate the cellular membrane penetration and efficient endosomal/lysosomal evasion of liposomal siRNA. A series of investigations demonstrated that once exposed to an acidic pH, the ACPP-modified liposomes showed elevated cellular uptake, downregulated expression of polo-like kinase 1, and augmented cell apoptosis. In addition, favorable siRNA avoidance of the endosome/lysosome was observed in both MCF-7 and A549 cells, followed by effective cytoplasmic release. In view of its acid sensitivity and therapeutic potency, this newly developed pH-responsive and ACPP-mediated liposome system represents a potential platform for siRNA-based cancer treatment.
Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging

Yi-Hsuan Chi,Jong-Kai Hsiao,Ming-Huang Lin,Chen Chang,Chun-Hsin Lan,Han-Chung Wu

DOI: https://doi.org/10.7150/thno.17573

IF: 11.6

2017-01-01

Theranostics

Abstract:Lung cancer is the leading cause of cancer-related death worldwide. Most targeted drugs approved for lung cancer treatment are tyrosine kinase inhibitors (TKIs) directed against EGFR or ALK, and are used mainly for adenocarcinoma. At present, there is no effective or tailored targeting agent for large cell carcinoma (LCC) or small cell lung cancer (SCLC). Therefore, we aimed to identify targeting peptides with diagnostic and therapeutic utility that possess broad subtype specificity for SCLC and non-small cell lung cancer (NSCLC). We performed phage display biopanning of H460 LCC cells to select broad-spectrum lung cancer-binding peptides, since LCC has recently been categorized as an undifferentiated tumor type within other histological subcategories of lung cancer. Three targeting phages (HPC1, HPC2, and HPC4) and their respective displayed peptides (HSP1, HSP2, and HSP4) were able to bind to both SCLC and NSCLC cell lines, as well as clinical specimens, but not to normal pneumonic tissues. In vivo optical imaging of phage homing and magnetic resonance imaging (MRI) of peptide-SPIONs revealed that HSP1 was the most favorable probe for multimodal molecular imaging. Using HSP1-SPION, the T2-weighted MR signal of H460 xenografts was decreased up to 42%. In contrast to the tight binding of HSP1 to cancer cell surfaces, HSP4 was preferentially endocytosed and intracellular drug delivery was thereby effected, significantly improving the therapeutic index of liposomal drug in vivo. Liposomal doxorubicin (LD) conjugated to HSP1, HSP2, or HSP4 had significantly greater therapeutic efficacy than non-targeting liposomal drugs in NSCLC (H460 and H1993) animal models. Combined therapy with an HSP4-conjugated stable formulation of liposomal vinorelbine (sLV) further improved median overall survival (131 vs. 84 days; P = 0.0248), even in aggressive A549 orthotopic models. Overall, these peptides have the potential to guide a wide variety of tailored theranostic agents for targeting therapeutics, non-invasive imaging, or clinical detection of SCLC and NSCLC.

medicine, research & experimental

Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients.

Molecular Mechanism of Anti-Cancer Activity of the Nano-Drug C-PC/CMC-CD59sp NPs in Cervical Cancer

A novel navigated doxorubicin delivery formulation to breast cancer therapy

The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with High-Affinity Peptides Discovered by Phage Display.

Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging.

A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

Ca2+ signaling modulation using cancer cell membrane coated chitosan nanoparticles to combat multidrug resistance of cancer

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell

A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Core-shell Tecto Dendrimers Co-Deliver Drug/gene for Immunomodulation of Macrophages and Dendritic Cells and Checkpoint Blockade-Promoted Breast Cancer Chemoimmunotherapy

The association of placental abnormalities with maternal and neonatal clinical findings: a retrospective cohort study.

Peptide-conjugated Nanoparticles for Targeted Imaging and Therapy of Prostate Cancer

Construction of a Targeting Nanoparticle of 3′,3″-Bis-peptide-sirna Conjugate/Mixed Lipid with Postinserted DSPE-PEG2000-cRGD

Dual-blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.

Cascade-Targeting of Charge-Reversal and Disulfide Bonds Shielding for Efficient DOX Delivery of Multistage Sensitive MSNs-COS-SS-CMC

Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

Sonication can reduce beta-lactamase activity.

Research priorities on safety of complementary feeding.

Enhancing Sirna-Based Cancer Therapy Using a New Ph-Responsive Activatable Cell-Penetrating Peptide-Modified Liposomal System

Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging